[20 phot. de l'Andalousie après le tremblement de terre de la fin de 1884, provenant de la mission française dirigée par F. Fouqué. Voir l'article de ce dernier dans le n°311, du 14 mars 1886, du Bulletin hebdomadaire de l'Association scientifique de France. Don Fouqué en 1886]

Donateur : Fouqué, Ferdinand (1828-1904)

Contribution à une étude normative de l'épreuve de Rorschach auprès d'un groupe d'enfants de 8 à 14 ans non-consultants

Cette étude normative de l'épreuve de Rorschach porte sur une population suisse de 102 enfants et adolescents non-consultants de 8 à 14 ans, répartis par tranches d'âge, sexe et niveau intellectuel. Elle présente un aperçu des différentes méthodes utilisées dans l'interprétation du Rorschach et des normes francophones existantes. Une réflexion est aussi proposée autour de la question de l'utilité de l'analyse des facteurs quantitatifs au Rorschach. Suite à une présentation détaillée de la méthodologie de recherche, les résultats sont exposés et comparés aux normes antérieures. Ils ne révèlent pas de différences importantes avec ces dernières, à l'exception de la hausse du F%, de la baisse du F+% et du nombre de Banalités. Les comparaisons Age, Sexe et QI révèlent quelques différences entre les groupes.

Evaluation of the prenatal diagnosis of limb reduction deficiencies. EUROSCAN Study Group.

Ultrasound scans in the mid-trimester of pregnancy are now a routine part of antenatal care in most European countries. Using data from registries of congenital anomalies a study was undertaken in Europe. The objective of the study was to evaluate prenatal detection of limb reduction deficiencies (LRD) by routine ultrasonographic examination of the fetus. All LRDs suspected prenatally and all LRDs (including chromosome anomalies) confirmed at birth were identified from 20 Congenital Malformation Registers from the following 12 European countries: Austria, Croatia, Denmark, France, Germany, Italy, Lithuania, Spain, Switzerland, The Netherlands, UK and Ukrainia. These registries are following the same methodology. During the study period (1996-98) there were 709,030 births, and 7,758 cases with congenital malformations including LRDs. If more than one LRD was present the case was coded as complex LRD; 250 cases of LRDs with 63 (25.2%) termination of pregnancies were identified including 138 cases with isolated LRD, 112 with associated malformations, 16 with chromosomal anomalies and 38 non chromosomal recognized syndromes. The prenatal detection rate of isolated LRD was 24.6% (34 out of 138 cases) compared with 49.1% for associated malformations (55 out of 112; p<0.01). The prenatal detection of isolated terminal transverse LRD was 22.7% (22 out of 97), 50% (3 out of 6) for proximal intercalary LRD, 8.3% (1 out of 12) for longitudinal LRD and 0 for split hand/foot; for multipli-malformed children with LRD those percentages were 46.1% (30 out of 65), 66.6% (6 out of 9), 57.1% (8 out of 14) and 0 (0 out of 2), respectively. The prenatal detection rate of LRDs varied in relation with the ultrasound screening policies from 20.0% to 64.0% in countries with at least one routine fetal scan.

Hominoid fission of chromosome 14/15 and the role of segmental duplications.

Ape chromosomes homologous to human chromosomes 14 and 15 were generated by a fission event of an ancestral submetacentric chromosome, where the two chromosomes were joined head-to-tail. The hominoid ancestral chromosome most closely resembles the macaque chromosome 7. In this work, we provide insights into the evolution of human chromosomes 14 and 15, performing a comparative study between macaque boundary region 14/15 and the orthologous human regions. We construct a 1.6-Mb contig of macaque BAC clones in the region orthologous to the ancestral hominoid fission site and use it to define the structural changes that occurred on human 14q pericentromeric and 15q subtelomeric regions. We characterize the novel euchromatin-heterochromatin transition region (∼20 Mb) acquired during the neocentromere establishment on chromosome 14, and find it was mainly derived through pericentromeric duplications from ancestral hominoid chromosomes homologous to human 2q14-qter and 10. Further, we show a relationship between evolutionary hotspots and low-copy repeat loci for chromosome 15, revealing a possible role of segmental duplications not only in mediating but also in "stitching" together rearrangement breakpoints.

Population pharmacokinetics of teicoplanin in children.

Teicoplanin is frequently administered to treat Gram-positive infections in pediatric patients. However, not enough is known about the pharmacokinetics (PK) of teicoplanin in children to justify the optimal dosing regimen. The aim of this study was to determine the population PK of teicoplanin in children and evaluate the current dosage regimens. A PK hospital-based study was conducted. Current dosage recommendations were used for children up to 16 years of age. Thirty-nine children were recruited. Serum samples were collected at the first dose interval (1, 3, 6, and 24 h) and at steady state. A standard 2-compartment PK model was developed, followed by structural models that incorporated weight. Weight was allowed to affect clearance (CL) using linear and allometric scaling terms. The linear model best accounted for the observed data and was subsequently chosen for Monte Carlo simulations. The PK parameter medians/means (standard deviation [SD]) were as follows: CL, [0.019/0.023 (0.01)] × weight liters/h/kg of body weight; volume, 2.282/4.138 liters (4.14 liters); first-order rate constant from the central to peripheral compartment (Kcp), 0.474/3.876 h(-1) (8.16 h(-1)); and first-order rate constant from peripheral to central compartment (Kpc), 0.292/3.994 h(-1) (8.93 h(-1)). The percentage of patients with a minimum concentration of drug in serum (Cmin) of <10 mg/liter was 53.85%. The median/mean (SD) total population area under the concentration-time curve (AUC) was 619/527.05 mg · h/liter (166.03 mg · h/liter). Based on Monte Carlo simulations, only 30.04% (median AUC, 507.04 mg · h/liter), 44.88% (494.1 mg · h/liter), and 60.54% (452.03 mg · h/liter) of patients weighing 50, 25, and 10 kg, respectively, attained trough concentrations of >10 mg/liter by day 4 of treatment. The teicoplanin population PK is highly variable in children, with a wider AUC distribution spread than for adults. Therapeutic drug monitoring should be a routine requirement to minimize suboptimal concentrations. (This trial has been registered in the European Clinical Trials Database Registry [EudraCT] under registration number 2012-005738-12.).

Informação/educação em DST/AIDS/sexualidade humana - um relato de experiência de 14 anos

As autoras relatam suas experiências de 14 anos sobre informação/educação em Doenças Sexualmente Transmissíveis/Aids e Sexualidade Humana. Descrevem as ações implementadas, destacando os resultados positivos, bem como os negativos. Quanto aos resultados positivos destacam evidentemente a divulgação de informações sobre medidas preventivas acerca da infecção pelo HIV/AIDS, DST e aspectos da sexualidade humana a diversos segmentos da comunidade leiga e científica, bem como, o repasse do aprendizado adquirido nessas vivencias para o ensino de graduação, pós-graduação e desenvolvimento da pesquisa. Quanto aos negativos, perceberam a dificuldade em avaliar as ações de informações, ou seja palestras, por constituírem-se uma estratégia de comunicação praticamente unilateral. Nessa trajetória apontam alguns fatos que historicamente marcaram a implementação de ações oficiais.

Mémoire pour Loüis Royer, peintre & conseiller de l'Académie, intimé & défendeur, contre Pierre Le Cerf, sellier-carrossier, Catherine Rabot, sa femme, auparavant veuve Joseph Naudin de la Vallée,... et Loüis-François Naudin de la Vallée, Geneviève Naudin de la Vallée,... appelans de sentences des consuls des 11 et 14 juin 1723... / (Monsieur l'abbé Pucelle , Rapporteur. Lamy, Procureur)

[Factum. Royer, Louis (peintre). 1725]

Lottery Action, July 22-August 4, 2002, Vol. 9 no. 14

Iowa Lottery Authority Retailer Information Newsletter

A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer.

BACKGROUND: Physicians need a specific risk-stratification tool to facilitate safe and cost-effective approaches to the management of patients with cancer and acute pulmonary embolism (PE). The objective of this study was to develop a simple risk score for predicting 30-day mortality in patients with PE and cancer by using measures readily obtained at the time of PE diagnosis. METHODS: Investigators randomly allocated 1,556 consecutive patients with cancer and acute PE from the international multicenter Registro Informatizado de la Enfermedad TromboEmbólica to derivation (67%) and internal validation (33%) samples. The external validation cohort for this study consisted of 261 patients with cancer and acute PE. Investigators compared 30-day all-cause mortality and nonfatal adverse medical outcomes across the derivation and two validation samples. RESULTS: In the derivation sample, multivariable analyses produced the risk score, which contained six variables: age > 80 years, heart rate ≥ 110/min, systolic BP < 100 mm Hg, body weight < 60 kg, recent immobility, and presence of metastases. In the internal validation cohort (n = 508), the 22.2% of patients (113 of 508) classified as low risk by the prognostic model had a 30-day mortality of 4.4% (95% CI, 0.6%-8.2%) compared with 29.9% (95% CI, 25.4%-34.4%) in the high-risk group. In the external validation cohort, the 18% of patients (47 of 261) classified as low risk by the prognostic model had a 30-day mortality of 0%, compared with 19.6% (95% CI, 14.3%-25.0%) in the high-risk group. CONCLUSIONS: The developed clinical prediction rule accurately identifies low-risk patients with cancer and acute PE.

Lottery Action, July 14-27, 2003, Vol. 10, no. 14

Newsletter for Iowa Lottery.